When was XyloCor Therapeutics founded?

XyloCor Therapeutics was founded in 2013 and raised its 1st funding round 3 years after it was founded.

Where is XyloCor Therapeutics located?

XyloCor Therapeutics is headquartered in Newtown Square, United States.

Is XyloCor Therapeutics a funded company?

XyloCor Therapeutics is a funded company, having raised a total of $111M across 8 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 17, 2016.

When was the latest funding round of XyloCor Therapeutics?

XyloCor Therapeutics' latest funding was a $***** Series B round on Jan 07, 2025, with participation from 4 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does XyloCor Therapeutics rank among its competitors?

XyloCor Therapeutics ranks 43rd amongst 559 active competitors, of which 201 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of XyloCor Therapeutics?

XyloCor Therapeutics' top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

XyloCor Therapeutics - 2026 Company Profile, Team, Funding & Competitors

XyloCor Therapeutics is a series B company based in Newtown Square (United States), founded in 2013 by Ronald Crystal. It operates as a Developer of gene therapies for the treatment of coronary arterial disease. XyloCor Therapeutics has raised $111M in funding from investors like Sofinnova Investments, Life Sciences Partners and Fountain Healthcare Partners. The company has 559 active competitors, including 201 funded and 133 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

XyloCor Therapeutics is developing gene therapies for coronary arterial disease. Its lead candidate, XC001, is for patients with refractory angina with no treatment options, and its secondary product for patients with cardiac tissue damage from heart attacks. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. The second candidate, XC002 is in the discovery stage and involves the regeneration of cardiac tissue for cases with past heart attacks.

Key Metrics

Founded Year

2013

Location

Newtown Square, United States

Stage

Series B

Total Funding

$111M in 8 rounds

Latest Funding Round

Series B, Jan 07, 2025, $*****

Investors

Sofinnova Investments & 6 more

Ranked

43^rd among 559 active competitors

Similar Companies

Alnylam & 701 more

View XyloCor Therapeutics' full profile

XyloCor Therapeutics has raised a total funding of $111M over 8 rounds. Its first funding round was on Nov 17, 2016. Its latest funding round was a Series B round on Jan 07, 2025 for $*****. 4 investors participated in its latest round. XyloCor Therapeutics has 7 institutional investors.

Here is the list of recent funding rounds of XyloCor Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2025	2654875	Series B	6684267	2982003	6706359	5167106
Mar 22, 2021	6993248	Series A	1723565	9430490	3398227	Longwood Fund & 3 more
Jan 20, 2021	8671874	Series A	5770826	2609244	7925307	5583971

Access funding benchmarks and valuations. Sign up today!

View details of XyloCor Therapeutics's funding rounds and investors

The founders of XyloCor Therapeutics is Ronald Crystal.

Here are the details of XyloCor Therapeutics' key team members:

Ronald Crystal: Co-Founder of XyloCor Therapeutics.
Contact Info: 1 email address

View details of XyloCor Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of XyloCor Therapeutics include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of XyloCor Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
43rd	XyloCor Therapeutics 2013, Newtown Square (United States), Series B	Developer of gene therapies for the treatment of coronary arterial disease	$111M	Life Sciences Partners, EQT & 5 others	60/100